

Status: Currently Official on 15-Feb-2025

Official Date: Official as of 01-May-2020

Document Type: USP Monographs

DocId: GUID-5DDC0F04-9CF5-41B9-8EE4-2F455BAA2169_4_en-US


DOI: https://doi.org/10.31003/USPNF_M55070_04_01

DOI Ref: ab1ub

© 2025 USPC

Do not distribute

Mycophenolate Mofetil

C₂₃H₃₁NO₇ 433.49

4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (E)-; 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate CAS RN[®]: 128794-94-5; UNII: 9242ECW6R0.

DEFINITION

Mycophenolate Mofetil contains NLT 98.0% and NMT 102.0% of mycophenolate mofetil (C₂₃H₃₁NO₇), calculated on the dried basis.

IDENTIFICATION

Change to read:

- **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy: 197K](#) ▲ (CN 1-MAY-2020)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Buffer: Triethylamine and water (1:325). Adjust with phosphoric acid to a pH of 5.3.

Mobile phase: Acetonitrile and *Buffer* (7:13)

Standard solution: 0.4 mg/mL of [USP Mycophenolate Mofetil RS](#) in acetonitrile

Sample solution: 0.4 mg/mL of Mycophenolate Mofetil in acetonitrile

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 250 nm

Column: 4.6-mm × 25-cm; 5-μm packing L7

Column temperature: 45°

Flow rate: 1.5 mL/min

Injection volume: 10 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 1.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of mycophenolate mofetil (C₂₃H₃₁NO₇) in the portion of Mycophenolate Mofetil taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Mycophenolate Mofetil RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Mycophenolate Mofetil in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the dried basis

IMPURITIES

- **RESIDUE ON IGNITION (281):** NMT 0.1%

- **ORGANIC IMPURITIES**

Buffer and Mobile phase: Prepare as directed in the Assay.

Sample solution: 2 mg/mL of Mycophenolate Mofetil in acetonitrile

System suitability solution: 10 µg/mL each of [USP Mycophenolate Mofetil Related Compound A RS](#) and [USP Mycophenolate Mofetil Related Compound B RS](#) in acetonitrile

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 250 nm

Column: 4.6-mm × 25-cm; 5-µm packing L7

Column temperature: 45°

Flow rate: 1.5 mL/min

Injection volume: 10 µL

System suitability

Sample: System suitability solution

Suitability requirements

Resolution: NLT 1.5 between mycophenolate mofetil related compound A and mycophenolate mofetil related compound B

Analysis

Sample: Sample solution

Calculate the percentage of each impurity in the portion of Mycophenolate Mofetil taken:

$$\text{Result} = (r_U/r_T) \times 100$$

r_U = peak response for each impurity

r_T = sum of all the peak responses

Acceptance criteria: See [Table 1](#). Disregard any peak less than 0.03%.

Table 1

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Mycophenolic acid ^a	0.33	0.50
Mycophenolate mofetil related compound A ^b	0.45	0.10
Mycophenolate mofetil related compound B ^c	0.49	0.10
N-Oxide analog ^d	0.60	0.10
1-Morpholinoethoxy analog ^e	0.86	0.10
Mycophenolate mofetil	1.0	—
Z-Mycophenolate mofetil ^f	1.1	0.10
O-Methyl analog ^g	1.2	0.10
Methyl mycophenolate ^h	1.5	0.10
Any single unspecified impurity	—	0.10
Total impurities	—	0.70

^a (E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid.

- ^b 2-Morpholinoethyl (*E*)-6-(1,3-dihydro-4,6-dihydroxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate.
- ^c (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-1-one.
- ^d 2-Morpholinoethyl (*E*)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate *N*-oxide.
- ^e 2-Morpholinoethyl (*RS*)-(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-1-(2-morpholinoethoxy)-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate.
- ^f 2-Morpholinoethyl (*Z*)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate.
- ^g 2-Morpholinoethyl (*E*)-6-(1,3-dihydro-4,6-dimethoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate.
- ^h Methyl (*E*)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate.

SPECIFIC TESTS

- [Loss on Drying \(731\)](#).

Analysis: Dry a sample under vacuum at 60° for 3 h.

Acceptance criteria: NMT 0.5%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers, and store at room temperature.

- **USP REFERENCE STANDARDS (11)**.

[USP Mycophenolate Mofetil RS](#)

[USP Mycophenolate Mofetil Related Compound A RS](#)

2-Morpholinoethyl (*E*)-6-(1,3-dihydro-4,6-dihydroxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate.

$C_{22}H_{29}NO_7$ 419.47

[USP Mycophenolate Mofetil Related Compound B RS](#)

(*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-1-one.

$C_{17}H_{20}O_6$ 320.34

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
MYCOPHENOLATE MOFETIL	Documentary Standards Support	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 37(6)

Current DocID: GUID-5DDC0F04-9CF5-41B9-8EE4-2F455BAA2169_4_en-US

DOI: https://doi.org/10.31003/USPNF_M55070_04_01

DOI ref: [ab1ub](#)